Elan reiterated by Merrill Lynch at sell

Elan Corp. plc was reiterated by Merrill Lynch at a sell rating. Ireland-based Elan is focused on autoimmune diseases, such as pain and neurodegenerative diseases. Elan shares on Thursday added 15 cents, or 2.25%, to close at $6.82 on volume of 6.57 million shares versus the three-month running average of 16.58 million.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.